NEWS September 20, 2023
Nirsevimab Resource Toolkit for Pediatric Practices
Summary
Nirsevimab, the new monoclonal antibody for prevention of RSV disease in infants and young children, has recently been approved by the FDA and recommended by the CDC and AAP. To assist in nirsevimab’s introduction into your practice, we have compiled a “toolkit” of resources covering everything from its recommended use to storage to coding and billing and more.
Nirsevimab, the new monoclonal antibody for prevention of RSV disease in infants and young children, has recently been approved by the FDA and recommended by the CDC and AAP. Its rollout presents an exciting opportunity to impact the health of these young children and their families! It also poses some operational challenges for pediatricians and our practices, especially over the next couple of months.
We look forward to collaborating on this effort and providing resources and support. Our commitment to your success in pediatric care remains steadfast. To assist in nirsevimab’s introduction into your practice, we have compiled a “toolkit” of resources covering everything from its recommended use to storage to coding and billing and more. Download the toolkit here.
As always, thank you for your partnership and all your efforts in caring for our community. Please reach out with any suggestions or questions. We will update resources and materials as we navigate this upcoming season together.
Gracias,
Eduardo Fox, M.D.
Medical Director
